Company profile
Theriva Biologics, Inc.
AMEX:TOVXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RIBAXAMASE | phase2 | — | 3 | active |
| Zabilugene Almadenorepvec | phase2 | — | 3 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02045589 | phase1 | completed | 2014-01-01 | 2016-10-01 | Theriva Biologics SL | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer |
| NCT02493036 | phase2 | completed | 2015-10-01 | 2015-12-01 | Theriva Biologics, Inc. | A Single-Dose, Open-Label, Study to Evaluate the Sustainability of the Effects of SYN-010 in Patients With IBS-C |
| NCT02473640 | phase1_2 | completed | 2015-06-01 | 2016-04-01 | Theriva Biologics, Inc. | A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy |
| NCT07701486 | phase1_2 | recruiting | 2026-08-03 | 2027-08-01 | Theriva Biologics SL | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer |
| NCT02563106 | phase2 | completed | 2015-10-01 | 2016-11-01 | Theriva Biologics, Inc. | A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI |
FDA applications (0)
No records yet.